An observational study in Advanced Non-small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Regeneron Pharmaceuticals · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals — 2 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Regeneron Pharmaceuticals.
Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is one of 3 that started in 2024, is one of 2 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 18th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals are open now, in 1 country. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 5
First in 2008; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 160 across 1,151 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 86 across the 18 interventional studies, 755 across the 2 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.
3 of the studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05785767Phase 3Regeneron PharmaceuticalsA Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | 2027-09-28 |
| NCT06269133Regeneron PharmaceuticalsEvaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants | 2027-03-31 |
| NCT04077099Regeneron PharmaceuticalsA Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | 2027-07-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multi-year cohort study will assess the real-world safety and effectiveness of first Line (1L) treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC participant subgroups defined by age, sex, race, and ethnicity. Participants will be retrospectively identified from at least two US Electronic Health Record (EHR)-based databases.
Participants and baseline variables will be captured retrospectively, but outcome measures will be prospectively ascertained.
Participants with advanced disease, defined as stage IIIB, IIIC, or IV disease, with evidence of administration of 1L cemiplimab in combination with platinum-doublet chemotherapy between 08 Nov 2022 and 30 Jun 2026 and without EGFR, ALK, or ROS1 genomic variants, or actively enrolled in a clinical trial in which they receive treatment with cemiplimab in combination with platinum-doublet chemotherapy.
Key Inclusion Criteria:
1. Advanced non-small cell lung cancer (aNSCLC) (defined as stage IIIB/C or stage IV) treated with cemiplimab in combination with platinum-doublet chemotherapy in the 1L setting from Nov 2022 to Jun 2026 as described in the protocol
Key Exclusion Criteria:
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Participants who have received cemiplimab in combination with platinum-doublet chemotherapy for the 1L treatment of aNSCLC in the US with no documented EGFR, ALK and ROS1 variants as described in the protocol.
Drug: REGN2810 · Other: Platinum-doublet chemotherapy
No study specific interventions for this non-interventional-observational study; participants had previously been administered this treatment.
Also known as: LIBTAYO®, cemiplimab
No study specific interventions for this non-interventional-observational study; participants had previously been administered this treatment.
Real-world Response Rate (rwRR)
Time frame: Approximately 3 years
Any treatment-emergent immune-mediated Adverse Event (imAE)
Time frame: Approximately 3 years
Any treatment-emergent imAE resulting in hospitalization
Time frame: Approximately 3 years
Any treatment-emergent imAE resulting in death
Time frame: Approximately 3 years
Specific treatment-emergent imAEs
Time frame: Approximately 3 years
Real-world Duration Of Response (rwDOR)
Time frame: Approximately 3 years
Real-world Progression-Free survival (rwPFS)
Time frame: Approximately 3 years
Real-world Overall Survival (rwOS)
Time frame: Approximately 3 years
imAEs
Time frame: Approximately 3 years
Infusion-Related Reaction (IRR)
Time frame: Approximately 3 years
IRR resulting in hospitalization
Time frame: Approximately 3 years
IRR resulting in death
Time frame: Approximately 3 years
Started Feb 2024 (actual). Primary completion is estimated for Mar 2027, 37 months after the start.
Of 142 industry-sponsored observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's planned 37 months is below that.
Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →